Cytosorbents (HQE) Financial Statements
0 Followers
Cytosorbents Financial Overview
Cytosorbents's market cap is currently $11.55M. The company's EPS TTM is $-5.75; its P/E ratio is -0.79; Cytosorbents is estimated to report earnings on November 12, 2026, and the estimated EPS forecast is $-0.80. See an overview of income statement, balance sheet, and cash flow financials.
| Dec 25 | Mar 25 | Dec 23 | Dec 22 | Dec 21 | |
|---|---|---|---|---|---|
| Income Statement | |||||
| Total Revenue | $ 37.06M | $ 35.59M | $ 31.08M | $ 34.69M | $ 40.11M |
| Gross Profit | $ 26.49M | $ 24.89M | $ 21.95M | $ 20.73M | $ 29.06M |
| Operating Income | $ -14.24M | $ -16.45M | $ -31.95M | $ -31.52M | $ -22.74M |
| EBITDA | $ -4.36M | $ -19.27M | $ -27.88M | $ -29.75M | $ -24.17M |
| Net Income | $ -8.20M | $ -20.72M | $ -29.25M | $ -32.81M | $ -24.56M |
| Balance Sheet | |||||
| Cash & Short-Term Investments | $ 6.25M | $ 3.28M | $ 14.13M | $ 22.14M | $ 52.14M |
| Total Assets | $ 44.18M | $ 47.37M | $ 53.26M | $ 63.23M | $ 89.52M |
| Total Debt | $ 29.11M | $ 26.89M | $ 18.31M | $ 18.25M | $ 13.82M |
| Net Debt | $ 22.86M | $ 23.61M | $ 4.18M | $ -3.89M | $ -38.32M |
| Total Liabilities | $ 38.28M | $ 36.26M | $ 29.99M | $ 27.86M | $ 26.94M |
| Stockholders' Equity | $ 5.90M | $ 11.11M | $ 23.28M | $ 35.37M | $ 62.58M |
| Cash Flow | |||||
| Free Cash Flow | $ -12.54M | $ -14.71M | $ -22.59M | $ -34.69M | $ -18.29M |
| Operating Cash Flow | $ -12.38M | $ -14.43M | $ -21.66M | $ -28.23M | $ -14.01M |
| Investing Cash Flow | $ -415.00K | $ -669.43K | $ -936.24K | $ -6.46M | $ -4.28M |
| Financing Cash Flow | $ 9.31M | $ 9.33M | $ 14.47M | $ 4.96M | $ 715.20K |
Currency in USD
